Product Portfolio
VeraMorph's DPOD platform is uniquely capable of nearly universal compatibility with poorly soluble drug substances. Considering about 40% of approved drug products are poorly soluble, and a majority are incompatible with current technologies, VeraMorph is developing novel, clinically-differentiated versions of approved products with the DPOD platform to create therapies that improve and prolong patient lives via a rapid and cost-effective R&D pathway.
Lead Product in Breast Cancer
VeraMorph is simultaneously validating the DPOD platform while enhancing survival and quality of life of metastatic breast cancer patients by developing an oral formulation of the approved monthly intramuscular version of fulvestrant.
Subsequent Reformulations
Due to the prevalence of poor solubility among approved prescription drug products across all disease areas, VeraMorph is leveraging the DPOD platform to rapidly and cost-effectively develop enhanced oral versions of roughly a dozen marketed drug products that improve patient lives.
VER001 - A differentiated oral SERD for Metastatic Breast Cancer
Metastatic breast cancer (mBC) causes about 45,000 women to die each year in the United States alone. There are many therapies that have extended survival of mBC patients, including fulvestrant, which is a highly potent & safe selective estrogen receptor degrader (SERD), but it is also poorly soluble and incompatible with available oral drug delivery technologies. As such, the approved injectable drug product does not enable fulvestrant to achieve the maximum possible survival for patients that it would be capable of if a technology were available to deliver a higher quantity of drug. Therefore, an oral version of fulvestrant would achieve an optimal combination of maximum survival and quality of life that no current therapy is able to achieve. VeraMorph's DPOD platform has been proven to yield an effective oral fulvestrant.
While other oral SERDs are currently in development, several have been inferior to the current injectable formulation of fulvestrant while those that have shown improvements in progression-free survival did so only for patients with mutations to the ESR1 gene, which occurs in roughly 20% of the ER+ patient population. Therefore a more efficacious oral fulvestrant stands to improve outcomes for roughly 80% of ER+ mBC patients.
VeraMorph's oral fulvestrant product has been shown to achieve up to 20X plasma concentrations of the approved monthly intramuscular injection, which translates into about a 55% increase in tumor growth inhibition in animal models. These preclinical results are expected to translate into improved clinical outcomes and patient quality of life for those suffering from metastatic breast cancer.
Connect with Our Team
.webp)
.avif)
Have a question or need assistance? We're here to help! Reach out to us anytime, and our team will get back to you as soon as possible.
.png)